引用次数
引用: 12,368
H-指数: 62
I10-指数 : 140
出版物: 234
Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival
William E Carson III , Joseph M Unger , Jeffrey A Sosman , Lawrence E Flaherty
Cancer immunology research 2 ( 10) 981 -987
7
2014
NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines
Alena C. Jaime-Ramirez , Elizabeth L. McMichael , SriVidya Kondadasula , Cassandra C. Skinner
Cancer immunology research 4 ( 4) 323 -336
2
2016
Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON
Zhiwei Hu , Rulong Shen , Amanda Campbell , Elizabeth McMichael
Cancer immunology research 6 ( 6) 671 -684
9
2018
Signaling pathways involved in MDSC regulation.
Prashant Trikha , William E. Carson
Biochimica et Biophysica Acta 1846 ( 1) 55 -65
197
2014
Review of S100A9 Biology and its Role in Cancer
Joseph Markowitz , William E. Carson
Biochimica et Biophysica Acta 1835 ( 1) 100 -109
171
2013
Distress reduction from a psychological intervention contributes to improved health for cancer patients
Barbara L. Andersen , William B. Farrar , Deanna Golden-Kreutz , Charles F. Emery
Brain Behavior and Immunity 21 ( 7) 953 -961
149
2007
Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Dan Shu , Hui Li , Yi Shu , Gaofeng Xiong
ACS Nano 9 ( 10) 9731 -9740
229
2015
A pilot study of bevacizumab and interferon-α2b in ocular melanoma.
Kristan D. Guenterberg , Valerie P. Grignol , Kiran V. Relekar , Kimberly A. Varker
American Journal of Clinical Oncology 34 ( 1) 87 -91
13
2011
Phase I Study of the Sequential Combination of Interleukin-12 and Interferon Alfa-2b in Advanced Cancer: Evidence for Modulation of Interferon Signaling Pathways by Interleukin-12
Charles F. Eisenbeis , Gregory B. Lesinski , Mirela Anghelina , Robin Parihar
Journal of Clinical Oncology 23 ( 34) 8835 -8844
20
2005
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
Steven K. Clinton , Thomas Olencki , Paul Monk , Elaine Lam
Journal of Immunotherapy 37 ( 3) 180 -186
9
2014
Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy.
Lorena P. Suarez-Kelly , Amanda R. Campbell , Isaac V. Rampersaud , Ambika Bumb
Nanomedicine: Nanotechnology, Biology and Medicine 13 ( 3) 909 -920
30
2017
Interleukin-21 enhances NK cell activation in response to antibody-coated targets.
Julie M. Roda , Robin Parihar , Amy Lehman , Aruna Mani
Journal of Immunology 177 ( 1) 120 -129
107
2006
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib
Emily M. McWilliams , Christopher R. Lucas , Timothy Chen , Bonnie K. Harrington
Blood Advances 3 ( 3) 447 -460
14
2019
Rat mitogen-stimulated lymphokine-activated T killer cells: production and effects on C6 glioma cells in vitro and in vivo in the brain of Wistar rats.
William E. Carson , James G. Jakowatz , Robert Yamamoto , Tom Fitzgerald
Journal of Immunotherapy 10 ( 2) 131 -140
11
1991
Impaired Natural Killer Cell Lysis in Breast Cancer Patients with High Levels of Psychological Stress is Associated with Altered Expression of Killer Immunoglobin-Like Receptors
Kimberly A. Varker , Catherine E. Terrell , Marilyn Welt , Samer Suleiman
Journal of Surgical Research 139 ( 1) 36 -44
36
2007
QS316. Enhanced in Vitro and in Vivo Anti-Tumor Activity of Bortezomib (Velcade®, PS-341) When Administered With Interferon-Alpha
Kristan D. Guenterberg , Gregory B. Lesinski , Nisha Shah , Ene Raig
Journal of Surgical Research 144 ( 2) 392
2008
Delayed emotional recovery after taxane-based chemotherapy.
Lisa M. Thornton , William E. Carson , Charles L. Shapiro , William B. Farrar
Cancer 113 ( 3) 638 -647
40
2008
A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial.
Lisa M. Thornton , Barbara L. Andersen , Tammy A. Schuler , William E. Carson
Psychosomatic Medicine 71 ( 7) 715 -724
90
2009
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab
Aruna Mani , Julie Roda , Donn Young , Michael A. Caligiuri
Breast Cancer Research and Treatment 117 ( 1) 83 -89
36
2009
Abstract A20: Analysis of tumor infiltrating lymphocytes and expression of PD1 and PD-L1 in breast tumors prior to and after neoadjuvant chemotherapy
Robert Wesolowski , Zaibo Li , Christopher McQuinn , Maryam Lustberg
Molecular Cancer Research 16
2018